Section Arrow
EXEL.NASDAQ
- Exelixis
Quotes are at least 15-min delayed:2026/01/06 20:17 EST
Regular Hours
Last
 43.68
+1.28 (+3.02%)
Day High 
43.93 
Prev. Close
42.4 
1-M High
47.24 
Volume 
2.38M 
Bid
43.66
Ask
43.68
Day Low
42.17 
Open
42.17 
1-M Low
40.66 
Market Cap 
11.37B 
Currency 美元 
P/E 17.82 
%Yield -- 
10-SMA 44.91 
20-SMA 43.42 
50-SMA 42.25 
52-W High 49.62 
52-W Low 31.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.38/4.17
Enterprise Value
11.56B
Balance Sheet
Book Value Per Share
8.06
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
10.50M
Operating Revenue Per Share
6.62
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.